HIV viral protein R causes atrial cardiomyocyte mitosis, mesenchymal tumor, dysrhythmia, and heart failure

Laboratory Investigation

Volumn 85, Issue 2, 2005, Pages 182-192

  Lewis, William ^a   Miller, Yoon K ^a   Haase, Chad P ^a   Ludaway, Tomika ^a   McNaught, Jamie ^a   Russ, Rodney ^a   Steltzer, Jeffrey ^a   Folpe, Andrew ^a   Long, Robert ^b   Oshinski, John ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

AIDS; Cardiac cell cycle; Cardiomyopathy; Mesenchyme

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; MYOSIN HEAVY CHAIN ALPHA; OSTEOGENIC PROTEIN 1; VPR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMEGALY; CELL CYCLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE CELL; HISTOPATHOLOGY; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE; MESENCHYMOMA; MITOSIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RR INTERVAL; TRANSGENIC MOUSE;

ANIMALS; ARRHYTHMIA; BIOLOGICAL MARKERS; CARDIOMEGALY; ELECTROCARDIOGRAPHY; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, VPR; HEART ATRIA; HEART FAILURE, CONGESTIVE; HEART NEOPLASMS; HIV-1; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; MITOSIS; MYOCARDIUM; MYOCYTES, CARDIAC; MYOSIN HEAVY CHAINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 13444310583     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700222     Document Type: Article

References (23)

1. Matsuda Z, Yu X, Yu QC, et al. A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:3544-3548.
2. Levy DN, Refaeli Y, MacGregor RR, et al. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994;91:10873-10877.
3. Tungaturthi PK, Sawaya BE, Singh SP, et al. Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intravirion, intracellular and free Vpr. Biomed Pharmacother 2003;57:20-24.
4. Levy DN, Fernandes LS, Williams WV, et al. Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell 1993;72:541-550.
5. Stewart SA, Poon B, Song JY, et al. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol 2000;74:3105-3111.
6. Lum JJ, Cohen OJ, Nie Z, et al. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 2003;111:1547-1554.
7. Reilly JM, Cunnion RE, Anderson DW, et al. Frequency of myocarditis, left ventricular dysfunction and ventricular tachycardia in the acquired immune deficiency syndrome. Am J Cardiol 1988;62:789-793.
8. Chang F, Re F, Sebastian S, et al. HIV-1 Vpr induces defects in mitosis, cytokinesis, nuclear structure, and centrosomes. Mol Biol Cell 2004;15:1793-1801.
9. de Noronha CM, Sherman MP, Lin HW, et al. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 2001;294:1105-1108.
10. Dalloz F, Osinska H, Robbins J. Manipulating the contractile apparatus: genetically defined animal models of cardiovascular disease. J Mol Cell Cardiol 2001;33:9-25.
11. Robbins J. Remodeling the cardiac sarcomere using transgenesis. Annu Rev Physiol 2000;62:261-287.
12. Subramaniam A, Jones WK, Gulick J, et al. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem 1991;266:24613-24620.
13. Raidel SM, Haase C, Jansen NR, et al. Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am J Physiol Heart Circ Physiol 2002;282:H1672-H1678.
14. Chu V, Otero JM, Lopez O, et al. Electrocardiographic findings in mdx mice: a cardiac phenotype of Duchenne muscular dystrophy. Muscle Nerve 2002;26:513-519.
15. Chu V, Otero JM, Lopez O, et al. Method for noninvasively recording electrocardiograms in conscious mice. BMC Physiol 2001;1:6.
16. Sutliff RL, Haase C, Russ R, et al. Cocaine increases mortality and cardiac mass in a murine transgenic model of acquired immune deficiency syndrome. Lab Invest 2003;83:983-989.
17. Mitchell GF, Jeron A, Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol 1998;274:H747-H751.
18. Gehrmann J, Hammer PE, Maguire CT, et al. Phenotypic screening for heart rate variability in the mouse. Am J Physiol Heart Circ Physiol 2000;279:H733-H740.
19. Lewis W, Haase CP, Raidel SM, et al. Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Lab Invest 2001;81:1527-1536.
20. Lewis W, Grupp IL, Grupp G, et al. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000;80:187-197.
21. Lewis W. Pathologic changes in the hearts of patients with AIDS. In: Lipshultz SE (ed). Cardiology in AIDS. Chapman & Hall: New York, 1998, pp 233-254.
22. Delcarpio JB, Lanson Jr NA, Field LJ, et al. Morphological characterization of cardiomyocytes isolated from a transplantable cardiac tumor derived from transgenic mouse atria (AT-1 cells). Circ Res 1991;69:1591-1600.
23. Narayanan V. Tuberous sclerosis complex: genetics to pathogenesis. Pediatr Neurol 2003;29:404-409.